This website is intended only for healthcare professionals outside the UK.
All our specialties
Congresses
Stay up to date with the latest scientific information from international medical congresses.
All our specialties
Diseases
Explore disease information across relevant specialties
External site
By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.
Gilberto Lopes talks about why the results of the DESTINY-Lung01 trial of trastuzumab deruxtecan are so important for the subset of non-small-cell lung cancer patients with HER2 mutations, a population of unmet need.
This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.